186 related articles for article (PubMed ID: 30784634)
1. Effect of 10-valent pneumococcal conjugate vaccine on the incidence of radiologically-confirmed pneumonia and clinically-defined pneumonia in Kenyan children: an interrupted time-series analysis.
Silaba M; Ooko M; Bottomley C; Sande J; Benamore R; Park K; Ignas J; Maitland K; Mturi N; Makumi A; Otiende M; Kagwanja S; Safari S; Ochola V; Bwanaali T; Bauni E; Gleeson F; Deloria Knoll M; Adetifa I; Marsh K; Williams TN; Kamau T; Sharif S; Levine OS; Hammitt LL; Scott JAG
Lancet Glob Health; 2019 Mar; 7(3):e337-e346. PubMed ID: 30784634
[TBL] [Abstract][Full Text] [Related]
2. Effect of ten-valent pneumococcal conjugate vaccine on invasive pneumococcal disease and nasopharyngeal carriage in Kenya: a longitudinal surveillance study.
Hammitt LL; Etyang AO; Morpeth SC; Ojal J; Mutuku A; Mturi N; Moisi JC; Adetifa IM; Karani A; Akech DO; Otiende M; Bwanaali T; Wafula J; Mataza C; Mumbo E; Tabu C; Knoll MD; Bauni E; Marsh K; Williams TN; Kamau T; Sharif SK; Levine OS; Scott JAG
Lancet; 2019 May; 393(10186):2146-2154. PubMed ID: 31000194
[TBL] [Abstract][Full Text] [Related]
3. Population effect of 10-valent pneumococcal conjugate vaccine on nasopharyngeal carriage of Streptococcus pneumoniae and non-typeable Haemophilus influenzae in Kilifi, Kenya: findings from cross-sectional carriage studies.
Hammitt LL; Akech DO; Morpeth SC; Karani A; Kihuha N; Nyongesa S; Bwanaali T; Mumbo E; Kamau T; Sharif SK; Scott JA
Lancet Glob Health; 2014 Jul; 2(7):e397-405. PubMed ID: 25103393
[TBL] [Abstract][Full Text] [Related]
4. Assessing the efficiency of catch-up campaigns for the introduction of pneumococcal conjugate vaccine: a modelling study based on data from PCV10 introduction in Kilifi, Kenya.
Flasche S; Ojal J; Le Polain de Waroux O; Otiende M; O'Brien KL; Kiti M; Nokes DJ; Edmunds WJ; Scott JAG
BMC Med; 2017 Jun; 15(1):113. PubMed ID: 28592303
[TBL] [Abstract][Full Text] [Related]
5. Assessment of health benefits and cost-effectiveness of 10-valent and 13-valent pneumococcal conjugate vaccination in Kenyan children.
Ayieko P; Griffiths UK; Ndiritu M; Moisi J; Mugoya IK; Kamau T; English M; Scott JA
PLoS One; 2013; 8(6):e67324. PubMed ID: 23826268
[TBL] [Abstract][Full Text] [Related]
6. Effect of ten-valent pneumococcal conjugate vaccine introduction on pneumonia hospital admissions in Fiji: a time-series analysis.
Reyburn R; Tuivaga E; Nguyen CD; Ratu FT; Nand D; Kado J; Tikoduadua L; Jenkins K; de Campo M; Kama M; Devi R; Rafai E; Weinberger DM; Mulholland EK; Russell FM
Lancet Glob Health; 2021 Jan; 9(1):e91-e98. PubMed ID: 33227258
[TBL] [Abstract][Full Text] [Related]
7. Effect of the of 10-valent pneumococcal conjugate vaccine in Nepal 4 years after introduction: an observational cohort study.
Shrestha S; Gurung M; Amatya P; Bijukchhe S; Bose AS; Carter MJ; Gautam MC; Gurung S; Hinds J; Kandasamy R; Kelly S; Khadka B; Maskey P; Mujadidi YF; O'Reilly PJ; Pokhrel B; Pradhan R; Shah GP; Shrestha S; Wahl B; O'Brien KL; Knoll MD; Murdoch DR; Kelly DF; Thorson S; Voysey M; Pollard AJ;
Lancet Glob Health; 2022 Oct; 10(10):e1494-e1504. PubMed ID: 36113533
[TBL] [Abstract][Full Text] [Related]
8. Effectiveness of ten-valent pneumococcal conjugate vaccine against invasive pneumococcal disease in Brazil: a matched case-control study.
Domingues CM; Verani JR; Montenegro Renoiner EI; de Cunto Brandileone MC; Flannery B; de Oliveira LH; Santos JB; de Moraes JC;
Lancet Respir Med; 2014 Jun; 2(6):464-71. PubMed ID: 24726406
[TBL] [Abstract][Full Text] [Related]
9. Effectiveness of ten-valent pneumococcal conjugate vaccine on invasive pneumococcal disease among children <2 years old: A prospective population-based study in rural Bangladesh.
Malaker R; Hasanuzzaman M; Hooda Y; Rahman H; Chandra Das R; Kanon N; Saha S; Tanmoy AM; Ranjan Chakraborty S; Saha S; Islam M; Darmstadt GL; Baqui AH; Sathosam M; El-Arifeen S; Whitney CG; Saha SK
Vaccine; 2024 Jan; 42(2):255-262. PubMed ID: 38071104
[TBL] [Abstract][Full Text] [Related]
10. Population immunity to pneumococcal serotypes in Kilifi, Kenya, before and 6 years after the introduction of PCV10 with a catch-up campaign: an observational study of cross-sectional serosurveys.
Gallagher KE; Adetifa IMO; Mburu C; Bottomley C; Akech D; Karani A; Pearce E; Wang Y; Kagucia EW; Goldblatt D; Hammitt LL; Scott JAG
Lancet Infect Dis; 2023 Nov; 23(11):1291-1301. PubMed ID: 37429307
[TBL] [Abstract][Full Text] [Related]
11. Systematic review on the impact of the pneumococcal conjugate vaccine ten valent (PCV10) or thirteen valent (PCV13) on all-cause, radiologically confirmed and severe pneumonia hospitalisation rates and pneumonia mortality in children 0-9 years old.
Reyburn R; Tsatsaronis A; von Mollendorf C; Mulholland K; Russell FM;
J Glob Health; 2023 Feb; 13():05002. PubMed ID: 36734192
[TBL] [Abstract][Full Text] [Related]
12. Sustained reduction in vaccine-type invasive pneumococcal disease despite waning effects of a catch-up campaign in Kilifi, Kenya: A mathematical model based on pre-vaccination data.
Ojal J; Flasche S; Hammitt LL; Akech D; Kiti MC; Kamau T; Adetifa I; Nurhonen M; Scott JAG; Auranen K
Vaccine; 2017 Aug; 35(35 Pt B):4561-4568. PubMed ID: 28729018
[TBL] [Abstract][Full Text] [Related]
13. Impact of the introduction of pneumococcal conjugate vaccination on invasive pneumococcal disease and pneumonia in The Gambia: 10 years of population-based surveillance.
; Mackenzie GA; Hill PC; Jeffries DJ; Ndiaye M; Sahito SM; Hossain I; Uchendu U; Ameh D; Adeyemi O; Pathirana J; Olatunji Y; Abatan B; Muhammad BS; Ahameefula E; Fombah AE; Adeshola B; Lobga BG; Saha D; Mackenzie R; Odutola A; Plumb ID; Akano A; Ebruke BE; Ideh RC; Kuti B; Githua P; Olutunde E; Ofordile O; Green E; Usuf E; Badji H; Ikumapayi UN; Manjang A; Salaudeen R; Nsekpong ED; Jarju S; Antonio M; Sambou S; Ceesay L; Lowe-Jallow Y; Fofana S; Jasseh M; Mulholland K; Knoll M; Levine OS; Howie SR; Adegbola RA; Greenwood BM; Corrah T
Lancet Infect Dis; 2021 Sep; 21(9):1293-1302. PubMed ID: 34280357
[TBL] [Abstract][Full Text] [Related]
14. Pneumococcal carriage and antibiotic susceptibility patterns from two cross-sectional colonization surveys among children aged <5 years prior to the introduction of 10-valent pneumococcal conjugate vaccine - Kenya, 2009-2010.
Kobayashi M; Conklin LM; Bigogo G; Jagero G; Hampton L; Fleming-Dutra KE; Junghae M; Carvalho MD; Pimenta F; Beall B; Taylor T; Laserson KF; Vulule J; Van Beneden C; Kim L; Feikin DR; Whitney CG; Breiman RF
BMC Infect Dis; 2017 Jan; 17(1):25. PubMed ID: 28056828
[TBL] [Abstract][Full Text] [Related]
15. Effect of 10-valent pneumococcal conjugate vaccine on nasopharyngeal carriage of Streptococcus pneumoniae and Haemophilus influenzae among children in São Paulo, Brazil.
Brandileone MC; Zanella RC; Almeida SCG; Brandao AP; Ribeiro AF; Carvalhanas TMP; Sato H; Andrade AL; Verani JR;
Vaccine; 2016 Nov; 34(46):5604-5611. PubMed ID: 27692770
[TBL] [Abstract][Full Text] [Related]
16. Effect of Haemophilus influenzae type b vaccination without a booster dose on invasive H influenzae type b disease, nasopharyngeal carriage, and population immunity in Kilifi, Kenya: a 15-year regional surveillance study.
Hammitt LL; Crane RJ; Karani A; Mutuku A; Morpeth SC; Burbidge P; Goldblatt D; Kamau T; Sharif S; Mturi N; Scott JA
Lancet Glob Health; 2016 Mar; 4(3):e185-94. PubMed ID: 26853149
[TBL] [Abstract][Full Text] [Related]
17. Effect of 13-valent pneumococcal conjugate vaccine on admissions to hospital 2 years after its introduction in the USA: a time series analysis.
Simonsen L; Taylor RJ; Schuck-Paim C; Lustig R; Haber M; Klugman KP
Lancet Respir Med; 2014 May; 2(5):387-94. PubMed ID: 24815804
[TBL] [Abstract][Full Text] [Related]
18. Immunogenicity of a single-dose compared with a two-dose primary series followed by a booster dose of ten-valent or 13-valent pneumococcal conjugate vaccine in South African children: an open-label, randomised, non-inferiority trial.
Madhi SA; Mutsaerts EA; Izu A; Boyce W; Bhikha S; Ikulinda BT; Jose L; Koen A; Nana AJ; Moultrie A; Roalfe L; Hunt A; Goldblatt D; Cutland CL; Dorfman JR
Lancet Infect Dis; 2020 Dec; 20(12):1426-1436. PubMed ID: 32857992
[TBL] [Abstract][Full Text] [Related]
19. All-cause pneumonia hospitalizations in children <2 years old in sweden, 1998 to 2012: impact of pneumococcal conjugate vaccine introduction.
Berglund A; Ekelund M; Fletcher MA; Nyman L
PLoS One; 2014; 9(11):e112211. PubMed ID: 25379659
[TBL] [Abstract][Full Text] [Related]
20. Impact of 7-valent versus 10-valent pneumococcal conjugate vaccines on primary care consultations across various age groups in the Netherlands, 5 years after the switch: A time-series analysis.
Asogwa OA; de Hoog MLA; Bruijning-Verhagen PCJI
Vaccine; 2022 Jan; 40(2):334-343. PubMed ID: 34969546
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
